Prescription Patterns in Patients with Chronic Obstructive Pulmonary Disease and Osteoporosis

Objective Patients with chronic obstructive pulmonary disease (COPD) have a higher risk of osteoporosis. Few studies have addressed the prescription patterns in osteoporosis patients with COPD. The purpose of this study was to conduct a retrospective study of the prescription patterns in patients with COPD and osteoporosis in Taiwan. Methods The study was conducted with data from the Taiwan National Health Insurance Research Database from January 1, 2003, to December 31, 2016. We selected the COPD population in Taiwan older than 40 years with at least one prescription for a bronchodilator. We excluded patients who had osteoporosis, fracture, asthma, or cancer before the diagnosis of COPD. After the diagnosis of COPD, patients who did not have osteoporosis were also excluded. We followed this COPD and osteoporosis cohort until they had been prescribed medication for osteoporosis. Results There were 13,407 patients with COPD and osteoporosis who received osteoporosis treatment. Among the patients who received treatment, the majority were female (n = 9136), accounting for 68.14% of all treated patients. A total of 53.4% of the patients had been prescribed steroids least once within the last year before receiving a diagnosis of osteoporosis. A total of 34.61% of the patients received systemic corticosteroids with a daily dose equivalent to 5 mg of prednisolone within the 3 months prior to the diagnosis of osteoporosis. The older the patient was, the higher the probability of the prescription of medication for osteoporosis. Patients with depression had a high probability of receiving medication for osteoporosis with adjusted hazard ratio of 1.141 (95% confidence interval, 1.072–1.214). Conclusion The rate of prescriptions for the treatment of osteoporosis in patients with COPD was low. Physicians need to be aware of this issue and treat osteoporosis more aggressively in patients with COPD.

[1]  Y. Ha,et al.  Relationship of chronic obstructive pulmonary disease severity with early and late mortality in elderly patients with hip fracture. , 2019, Injury.

[2]  T. McKeever,et al.  Predicting fracture risk in patients with chronic obstructive pulmonary disease: a UK-based population-based cohort study , 2019, BMJ Open.

[3]  H. Yasunaga,et al.  Mortality associated with bone fractures in COPD patients , 2016, International journal of chronic obstructive pulmonary disease.

[4]  R. Okazaki,et al.  COPD and osteoporosis: links, risks, and treatment challenges , 2016, International journal of chronic obstructive pulmonary disease.

[5]  A. Casini,et al.  Effectiveness and safety of calcium and vitamin D treatment for postmenopausal osteoporosis. , 2015, Minerva endocrinologica.

[6]  H. Yamakawa,et al.  Osteoporosis is highly prevalent in Japanese males with chronic obstructive pulmonary disease and is associated with deteriorated pulmonary function , 2015, Journal of Bone and Mineral Metabolism.

[7]  K. Maes,et al.  Musculoskeletal Disorders in Chronic Obstructive Pulmonary Disease , 2014, BioMed research international.

[8]  P. Eskildsen,et al.  Time trends for alendronate prescription practices in women with chronic obstructive pulmonary disease and women exposed to systemic glucocorticoids , 2013, Osteoporosis International.

[9]  M. Decramer,et al.  Chronic obstructive pulmonary disease , 2012, The Lancet.

[10]  E. Wouters,et al.  Osteoporosis in COPD outpatients based on bone mineral density and vertebral fractures , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[11]  B. Rowe,et al.  Prevalence and predictors of vertebral fracture in patients with chronic obstructive pulmonary disease. , 2010, Respiratory medicine.

[12]  C. Jenkins,et al.  Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. , 2009, Chest.

[13]  E. Wouters,et al.  Correlates of osteoporosis in chronic obstructive pulmonary disease: An underestimated systemic component. , 2009, Respiratory medicine.

[14]  J. Bilezikian Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. , 2009, The American journal of medicine.

[15]  J. Carter,et al.  The recognition and treatment of vertebral fractures in males with chronic obstructive pulmonary disease. , 2008, Respiratory medicine.

[16]  A. Ionescu,et al.  Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. , 2004, American journal of respiratory and critical care medicine.

[17]  J. Vestbo,et al.  Chronic obstructive pulmonary disease as a systemic disease: an epidemiological perspective , 2003, European Respiratory Journal.

[18]  A. Green,et al.  Why the disease-based model of medicine fails our patients. , 2002, The Western journal of medicine.

[19]  H. Sørensen,et al.  Chronic obstructive pulmonary disease and mortality following hip fracture: a population-based cohort study , 2007, European Journal of Epidemiology.

[20]  D. Postma,et al.  Chronic obstructive pulmonary disease. , 2002, Clinical evidence.